Solid Tumor Cancer Treatment Market
Solid Tumor Cancer Treatment Market Size, Share & Trends Analysis Report by Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, and Cervical Cancer), by Drug Type (Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Doxorubicin, Bevacizumab, Erlotinib, Sunitinib, and Everolimusa), by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, and Surgical Procedures), and by End-User (Hospitals, Specialty Clinics, Research Institutes, and Homecare) Forecast Period (2023-2030) Update Available - Forecast 2024-2030
Solid tumor cancer treatment market is anticipated to grow at a CAGR of 12.5% during the forecast period. Solid tumor cancer treatment refers to a treatment of an aberrant mass of tissue that does not generally contain cysts or liquid regions. Solid tumors include cancers of the brain, ovary, breast, colon, and other organs. The majority of the tumor's cells are created by cancer stem cells through division.
The increasing incidence of cancer significantly contributes to the growth of the solid tumor cancer treatment market. For instance, according to the European Breast Cancer Coalition 2022 report, 1 in 11 women in the European Union develop breast cancer before the age of 74. According to 2021 statistics published by Breast Cancer Now, about 55,000 women are diagnosed with breast cancer in the UK every year. The same source reported that 46,000 people are diagnosed with breast cancer in England every year, followed by 4,700 in Scotland, 2,800 in Wales, and 1,500 in Northern Ireland. According to a report by the American Cancer Society, the estimated number of new cancer cases in the US in 2021 was 1,898,160, which increased to 1,918,030 in 2022.
The rising strategic initiatives by market players for the launch of advanced solid tumor therapeutics augment the market growth. For instance, in August 2021, GSK received FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for a new indication in adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors. The new indication received accelerated approval based on tumor response rate and durability of response. Such approvals are projected to boost market growth over the forecast period.
Segmental Outlook
The global solid tumor cancer treatment market is segmented based on type, drug type, therapy, and by end-user. Based on type, the market is sub-segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and cervical cancer. By drug type, the market is augmented into carboplatin, cisplatin, gemcitabine, paclitaxel, doxorubicin, bevacizumab, erlotinib, sunitinib, and everolimusa. By therapy, the market is segregated into chemotherapy, targeted therapy, immunotherapy, hormone therapy, and surgical procedures. Further, by end-user, the market is sub-segmented into hospitals, specialty clinics, research institutes, and homecare. Among the end-users, the hospitals sub-segment is expected to hold a prominent share of the market. This can be attributed to the collaboration with pharmaceutical companies and insurance providers, the availability of advanced treatment technologies, and multidisciplinary collaboration.
Breast Cancer Sub-Segment is Anticipated to Hold a Prominent Share of the Global Solid Tumor Cancer Treatment Market
The continuously growing burden of breast cancer globally is expected to boost the segmental growth. As per the report published by the Canadian Medical Association Journal in May 2022, around 28.6 thousand new breast cancer cases were diagnosed in Canada in 2022, which accounted for 25.0% of the total new cancer diagnosed in women in Canada. Additionally, according to the Australian Institute of Health and Welfare (AIHW) 2022 report, around 20.6 thousand new breast cancer cases were diagnosed in Australia. Moreover, according to an article published in the National Center of Biotechnology Information in February 2022, 429.1 thousand breast cancer cases were diagnosed in females in China in 2022. Apart from the rising incidences, drug approvals by government agencies is another factors further bolstering the sub-segment's growth. For instance, in February 2023, Gilead Sciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The drug has been proven to treat solid tumors in clinical trials.
Regional Outlook
The global solid tumor cancer treatment market is further segmented based on geography including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). Among these, the Asia-Pacific region is projected to expand at a significant CAGR during the forecast period, due to various factors such as increasing prevalence of solid tumor cancers, advancements in precision medicine, and increasing healthcare expenditure.
Global Solid Tumor Cancer Treatment Market Growth, by Region 2023-2030
North America is Anticipated to Hold a Significant Share of the Global Solid Tumor Cancer Treatment Market
The high burden of solid tumors such as breast, lung, and colorectal cancer in the region is driving the market growth. According to the American Cancer Society 2023 statistics, around 1.9 million new cancer cases were estimated to be diagnosed in the US in 2023, out of which an estimated 153.0 thousand colorectal cancer, 238.3 thousand lungs, and bronchus cancer were diagnosed in 2023. Resultantly, the region's high burden of new cancer cases is projected to boost the R&D for developing advanced solid tumor therapeutics which will drive the market growth. For instance, The Cancer Moonshot initiative launched by the US government back in 2016 to accelerate progress in cancer prevention, diagnosis, treatment, and care. Further, in February 2022, the US President Joe Biden reignited the Cancer Moonshot initiative, setting ambitious, achievable goals to reduce the death rate from cancer by at least 50.0% over the next 25 years. The President’s FY 2024 Budget makes strategic investments in the Cancer Moonshot as part of the President’s Unity Agenda to deliver new ways to prevent, detect, and treat cancer. The Budget includes a total investment of $7.8 billion for the National Cancer Institute (NCI), plus expected critical contributions from $2.5 billion for ARPA-H to help deliver on Moonshot goals.
Market Players Outlook
The major companies serving the global solid tumor cancer treatment market include Amgen Inc., AstraZeneca, Eli Lilly and Co., and F. Hoffman-La Roche Ltd., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, funding, collaborations, and new product launches to stay competitive in the market. For instance, in March 2021, Takeda Pharmaceutical acquired Maverick Therapeutics for worth $525.0 million. The acquisition provided Takeda the access to Maverick's T-cell engager COBRA platform and a diverse development portfolio, including TAK-186 (MVC-101) and TAK-280, the latter's main development candidate (MVC-280). With this acquisition, Takeda can expand its novel immuno-oncology portfolio to advance its redirected immunotherapies against solid tumors. Maverick Therapeutics Inc. is a US-based biotechnology company that provides T-cell targeted immunotherapies for solid tumor cancers.
The Report Covers
- Market value data analysis of 2022 and forecast to 2030.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global solid tumor cancer treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.2. Amgen Inc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. AstraZeneca
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Eli Lilly and Co.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. F. Hoffmann-La Roche Ltd.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
4. Market Segmentation
4.1. Global Solid Tumor Cancer Treatment Market by Type
4.1.1. Breast Cancer
4.1.2. Lung Cancer
4.1.3. Colorectal Cancer
4.1.4. Prostate Cancer
4.1.5. Cervical Cancer
4.2. Global Solid Tumor Cancer Treatment Market by Drug Type
4.2.1. Carboplatin
4.2.2. Cisplatin
4.2.3. Gemcitabine
4.2.4. Paclitaxel
4.2.5. Doxorubicin
4.2.6. Bevacizumab
4.2.7. Erlotinib
4.2.8. Sunitinib
4.2.9. Everolimusa
4.3. Global Solid Tumor Cancer Treatment Market by Therapy
4.3.1. Chemotherapy
4.3.2. Targeted Therapy
4.3.3. Immunotherapy
4.3.4. Hormone Therapy
4.3.5. Surgical Procedures
4.4. Global Solid Tumor Cancer Treatment Market by End-User
4.4.1. Hospitals
4.4.2. Specialty Clinics
4.4.3. Research Institutes
4.4.4. Homecare
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Allergan
6.2. B. Braun Melsungen AG
6.3. Bayer AG
6.4. Boehringer Ingelheim International GmbH
6.5. Bristol Myers Squibb & Company
6.6. Celgene Corp
6.7. Celldex Therapeutics Inc.
6.8. Dr. Reddy’s Laboratories Ltd.
6.9. Gilead Sciences, Inc.
6.10. GlaxoSmithKline PLC
6.11. Hikma Pharmaceuticals PLC
6.12. Lupin
6.13. Merck & Co. Inc.
6.14. Novartis AG
6.15. Olympus Medical Systems
6.16. Pfizer Inc
6.17. Takeda Pharmaceutical Company Ltd.
6.18. Teva Pharmaceutical Industries Ltd.
1. GLOBAL SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
2. GLOBAL BREAST CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
3. GLOBAL LUNG CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
4. GLOBAL COLORECTAL CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
5. GLOBAL PROSTATE CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
6. GLOBAL CERVICAL CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
7. GLOBAL SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
8. GLOBAL SOLID TUMOR CANCER TREATMENT BY CARBOPLATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
9. GLOBAL SOLID TUMOR CANCER TREATMENT BY CISPLATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
10. GLOBAL SOLID TUMOR CANCER TREATMENT BY GEMCITABINE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
11. GLOBAL SOLID TUMOR CANCER TREATMENT BY PACLITAXEL MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
12. GLOBAL SOLID TUMOR CANCER TREATMENT BY DOXORUBICIN MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
13. GLOBAL SOLID TUMOR CANCER TREATMENT BY BEVACIZUMAB MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
14. GLOBAL SOLID TUMOR CANCER TREATMENT BY ERLOTINIB MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
15. GLOBAL SOLID TUMOR CANCER TREATMENT BY SUNITINIB MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
16. GLOBAL SOLID TUMOR CANCER TREATMENT BY EVEROLIMUSA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
17. GLOBAL SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2022-2030 ($ MILLION)
18. GLOBAL SOLID TUMOR CANCER TREATMENT BY CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
19. GLOBAL SOLID TUMOR CANCER TREATMENT BY TARGETED THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
20. GLOBAL SOLID TUMOR CANCER TREATMENT BY IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
21. GLOBAL SOLID TUMOR CANCER TREATMENT BY HORMONE THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
22. GLOBAL SOLID TUMOR CANCER TREATMENT BY SURGICAL PROCEDURES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
23. GLOBAL SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
24. GLOBAL SOLID TUMOR CANCER TREATMENT IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
25. GLOBAL SOLID TUMOR CANCER TREATMENT IN SPECIALTY CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
26. GLOBAL SOLID TUMOR CANCER TREATMENT IN RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
27. GLOBAL SOLID TUMOR CANCER TREATMENT IN HOMECARE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
28. GLOBAL SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
29. NORTH AMERICAN SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
30. NORTH AMERICAN SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
31. NORTH AMERICAN SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2022-2030 ($ MILLION)
32. NORTH AMERICAN SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
33. NORTH AMERICAN SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
34. EUROPEAN SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
35. EUROPEAN SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
36. EUROPEAN SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
37. EUROPEAN SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2022-2030 ($ MILLION)
38. EUROPEAN SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
39. ASIA-PACIFIC SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
40. ASIA-PACIFIC SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
41. ASIA-PACIFIC SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
42. ASIA-PACIFIC SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2022-2030 ($ MILLION)
43. ASIA-PACIFIC SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
44. REST OF THE WORLD SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
45. REST OF THE WORLD SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
46. REST OF THE WORLD SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
47. REST OF THE WORLD SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2022-2030 ($ MILLION)
48. REST OF THE WORLD SOLID TUMOR CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
1. GLOBAL SOLID TUMOR CANCER TREATMENT MARKET SHARE BY TYPE, 2022 VS 2030 (%)
2. GLOBAL BREAST CANCER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
3. GLOBAL LUNG CANCER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
4. GLOBAL COLORECTAL CANCER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
5. GLOBAL PROSTATE CANCER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
6. GLOBAL CERVICAL TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
7. GLOBAL SOLID TUMOR CANCER TREATMENT MARKET SHARE BY DRUG TYPE, 2022 VS 2030 (%)
8. GLOBAL SOLID TUMOR CANCER TREATMENT BY CARBOPLATIN MARKET SHARE BY REGION, 2022 VS 2030 (%)
9. GLOBAL SOLID TUMOR CANCER TREATMENT BY CISPLATIN MARKET SHARE BY REGION, 2022 VS 2030 (%)
10. GLOBAL SOLID TUMOR CANCER TREATMENT BY GEMCITABINE MARKET SHARE BY REGION, 2022 VS 2030 (%)
11. GLOBAL SOLID TUMOR CANCER TREATMENT BY PACLITAXEL MARKET SHARE BY REGION, 2022 VS 2030 (%)
12. GLOBAL SOLID TUMOR CANCER TREATMENT BY DOXORUBICIN MARKET SHARE BY REGION, 2022 VS 2030 (%)
13. GLOBAL SOLID TUMOR CANCER TREATMENT BY BEVACIZUMAB MARKET SHARE BY REGION, 2022 VS 2030 (%)
14. GLOBAL SOLID TUMOR CANCER TREATMENT BY ERLOTINIB MARKET SHARE BY REGION, 2022 VS 2030 (%)
15. GLOBAL SOLID TUMOR CANCER TREATMENT BY SUNITINIB MARKET SHARE BY REGION, 2022 VS 2030 (%)
16. GLOBAL SOLID TUMOR CANCER TREATMENT BY EVEROLIMUSA MARKET SHARE BY REGION, 2022 VS 2030 (%)
17. GLOBAL SOLID TUMOR CANCER TREATMENT MARKET SHARE BY THERAPY, 2022 VS 2030 (%)
18. GLOBAL SOLID TUMOR CANCER TREATMENT BY CHEMOTHERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
19. GLOBAL SOLID TUMOR CANCER TREATMENT BY TARGETED THERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
20. GLOBAL SOLID TUMOR CANCER TREATMENT BY IMMUNOTHERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
21. GLOBAL SOLID TUMOR CANCER TREATMENT BY HORMONE THERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
22. GLOBAL SOLID TUMOR CANCER TREATMENT BY SURGICAL PROCEDURES MARKET SHARE BY REGION, 2022 VS 2030 (%)
23. GLOBAL SOLID TUMOR CANCER TREATMENT MARKET SHARE BY END-USER, 2022 VS 2030 (%)
24. GLOBAL SOLID TUMOR CANCER TREATMENT IN HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
25. GLOBAL SOLID TUMOR CANCER TREATMENT MARKET IN SPECIALTY CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
26. GLOBAL SOLID TUMOR CANCER TREATMENT IN RESEARCH INSTITUTES MARKET SHARE BY REGION, 2022 VS 2030 (%)
27. GLOBAL SOLID TUMOR CANCER TREATMENT IN HOMECARE MARKET SHARE BY REGION, 2022 VS 2030 (%)
28. GLOBAL SOLID TUMOR CANCER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
29. US SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
30. CANADA SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
31. UK SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
32. FRANCE SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
33. GERMANY SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
34. ITALY SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
35. SPAIN SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
36. REST OF EUROPE SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
37. INDIA SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
38. CHINA SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
39. JAPAN SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
40. SOUTH KOREA SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
41. REST OF ASIA-PACIFIC SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
42. REST OF THE WORLD SOLID TUMOR CANCER TREATMENT MARKET SIZE, 2022-2030 ($ MILLIO
